Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.170
+0.040 (1.88%)
Aug 14, 2025, 2:12 PM - Market open
Outlook Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
92.99M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OTLK News
- 6 hours ago - Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewsWire
- 23 days ago - Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer - GlobeNewsWire
- 2 months ago - Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewsWire